Jefferies Financial Group Inc. Makes New $2.11 Million Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Jefferies Financial Group Inc. acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 114,766 shares of the biopharmaceutical company's stock, valued at approximately $2,106,000. Jefferies Financial Group Inc. owned approximately 0.07% of ACADIA Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Virtus Fund Advisers LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at $39,000. R Squared Ltd bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $47,000. GF Fund Management CO. LTD. bought a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth $64,000. KBC Group NV boosted its position in shares of ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 2,044 shares in the last quarter. Finally, Globeflex Capital L P bought a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $168,000. Institutional investors own 96.71% of the company's stock.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 2,000 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the transaction, the executive vice president now owns 62,130 shares in the company, valued at approximately $1,553,250. This represents a 3.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider James Kihara sold 4,000 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $22.50, for a total value of $90,000.00. Following the sale, the insider now directly owns 20,395 shares in the company, valued at approximately $458,887.50. The trade was a 16.40% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,746 shares of company stock worth $428,221. 28.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Morgan Stanley set a $24.00 price target on ACADIA Pharmaceuticals and gave the company an "equal weight" rating in a research note on Tuesday, May 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Mizuho raised their price target on shares of ACADIA Pharmaceuticals from $20.00 to $23.00 and gave the company a "neutral" rating in a research report on Monday, May 19th. Wall Street Zen raised shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $26.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, May 19th. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.83.

ACADIA Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ:ACAD traded down $0.69 on Friday, hitting $21.60. 1,446,509 shares of the company were exchanged, compared to its average volume of 1,939,166. The firm has a market capitalization of $3.62 billion, a P/E ratio of 27.69 and a beta of 0.47. The stock's 50 day moving average price is $16.87 and its 200 day moving average price is $17.48. ACADIA Pharmaceuticals Inc. has a 1-year low of $13.40 and a 1-year high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The company had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. ACADIA Pharmaceuticals's quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. On average, equities analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.